SCHEMBL31714229

SCHEMBL31714229

Cc1cc(Br)c(OC(F)(F)F)cc1N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MBOAT4 Q96T53 1/20 0.38
CYP3A4 P08684 2/20 0.38
TSHR P16473 2/20 0.38
MAPK1 P28482 1/20 0.38
POLB P06746 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
GAA P10253 1/20 0.33
GFER P55789 1/20 0.33
ALDH1A1 P00352 4/20 0.32
CYP1A2 P05177 1/20 0.32
ALOX15 P16050 1/20 0.32
CASP7 P55210 1/20 0.32
HIF1A Q16665 1/20 0.32
HSD17B10 Q99714 1/20 0.32
CGAS Q8N884 1/20 0.32
AR P10275 1/20 0.32
HRH4 Q9H3N8 1/20 0.32
TERT O14746 1/20 0.31
PDE2A O00408 1/20 0.31
S1PR1 P21453 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30860858 0.92 POLB (0.39) MBOAT4CYP3A4TSHRMAPK1POLB
SCHEMBL27228391 0.92 POLB (0.39) MBOAT4CYP3A4TSHRMAPK1POLB
SCHEMBL16097407 0.86 L3MBTL1 (0.39) MBOAT4POLBL3MBTL1ALDH1A1ALOX15
SCHEMBL10261819 0.81 L3MBTL1 (0.60) CYP3A4TSHRMAPK1POLBL3MBTL1
SCHEMBL2681143 0.81 PDE2A (0.34) MBOAT4POLBL3MBTL1ALDH1A1PDE2A
SCHEMBL2650312 0.80 L3MBTL1 (0.42) MBOAT4POLBL3MBTL1ALDH1A1ALOX15
SCHEMBL30640833 0.79 L3MBTL1 (0.42) MBOAT4CYP3A4TSHRMAPK1POLB
SCHEMBL17304013 0.79 L3MBTL1 (0.42) MBOAT4CYP3A4TSHRMAPK1POLB
SCHEMBL2683377 0.79 NPC1 (0.41) MBOAT4POLBL3MBTL1GAA
SCHEMBL10978868 0.77 PDE2A (0.41) CYP3A4TSHRMAPK1POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025228900-A1 ARYLAMIDE SUBSTITUTED INDAZOLES AND THE USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-11-06 WO disclosed
US-20250333414-A1 HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2025-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250333414-A1 HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT STING1, MAVS, TBK1 MBOAT4 4547/4885CYP3A4 393/4885TSHR 4429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.